Apparatus, systems and methods for treating a human tissue condition

Information

  • Patent Grant
  • 8348938
  • Patent Number
    8,348,938
  • Date Filed
    Wednesday, May 6, 2009
    15 years ago
  • Date Issued
    Tuesday, January 8, 2013
    11 years ago
Abstract
Apparatus, systems and methods for providing electrical energy to treat a tissue condition includes a high voltage pulse generator for generating short high voltage pulses of energy and a delivery device for receiving the pulses of energy. The delivery device includes at least a pair of needle electrodes for penetrating into the tissue and delivering the pulses of energy to the tissue.
Description
FIELD

The present disclosure relates generally to apparatus and methods for providing electrical energy for tissue treatment.


BACKGROUND

U.S. Pat. No. 6,326,177 to Schoenbach et al., which is incorporated by reference herein in its entirety, describes an apparatus and method for intracellular electro-manipulation, including tissue treatment, using ultra short pulses. As taught by Schoenbach et al., target cells are subjected to one or more ultra short electric field pulses.


A general object of the subject matter disclosed herein is to therefore provide an improved delivery device for delivery of electrical energy for the treatment of a tissue condition.


Another general object of the subject matter disclosed herein is to provide an improved pulse generator for providing the electrical energy to the delivery device.


A further object of the subject matter disclosed herein is to provide a delivery device for delivery of electrical energy for the treatment of a tissue condition which is in the form of a dual or multiple needle assembly for penetration of the dermis.


Yet another object of the subject matter disclosed herein is to provide a dual or multiple needle assembly for the treatment of a tissue condition which is disposable.


A still further object of the subject matter disclosed herein is to provide insulation about portions of the dual or multiple needle assembly to protect the dermis during treatment of subcutaneous tissue.


Another object of the subject matter disclosed herein is to provide a pulse generator which generates low energy, high voltage pulses of short duration.


SUMMARY

The subject matter disclosed herein is directed to an apparatus, systems and methods for treating a tissue condition. In one embodiment, apparatus for providing electrical energy to human tissue to treat a tissue condition includes a high voltage pulse generator for generating a short high voltage pulse of energy at a pair of output terminals, a delivery device receives the short high voltage pulse of energy from the pulse generator, the delivery device preferably includes at least a pair of needle electrodes for penetrating into the human tissue and for delivering the short high voltage pulse of energy to tissue disposed between the needle electrodes.


The pair of needle electrodes of the delivery device preferably have uncoated ends, and have an insulative coating applied about proximal portions of the needle electrodes. The insulative coating may consist of parylene, polyimide, polyester, diamond, Teflon, or combinations of such materials, or another insulating material. When in use during a tissue treatment procedure, the uncoated portions of the needle electrodes are located in sub-dermal tissue and the coated portions of the needle electrodes are located in dermis. The short high voltage pulse may be in the range of about 10 to 500 nanoseconds in duration, and may provide average electric field strength of about 10 to 50 kilovolts/centimeter in the tissue. The tissue treatment procedure may include an intracellular electro-manipulation treatment or a plasma spark discharge.


In another embodiment, multiple needle electrodes will be used in an array. At any time, two selected electrodes will have the desired voltage applied across them. The selected electrodes may be selected with a switch, for example, based upon electromechanical relays.


In another embodiment, the subject matter disclosed herein is directed to a system for providing electrical energy to human tissue to treat a tissue condition. The system preferably includes a high voltage pulse generator for generating a short high voltage pulse of energy at a pair of output terminals, the pulse generator includes a spark gap which contains a pressurized gas and which emits a spark when the voltage across the spark gap exceeds the dielectric strength of the gas in the spark gap, a sensor for sensing the pressure of the pressurized gas in the spark gap and for providing a pressure signal related to the sensed pressure, means for adjusting the pressure in the spark gap to modify the magnitude of the voltage of the short high voltage pulse generated by the pulse generator, and a delivery device for receiving the short high voltage pulse of energy from the pulse generator and for applying the short high voltage pulse of energy to the tissue.


The means for adjusting the pressure in the spark gap may further include a controllable gas pressure regulator to supply gas pressure to the spark gap, means for selecting an initial voltage magnitude for the short high voltage pulse, means for determining the actual voltage magnitude of the short high voltage pulse and for providing a signal representative of the actual voltage magnitude of the short high voltage pulse, and a data processor for receiving the signal representative of the voltage magnitude of the short high voltage pulse, the data processor determining any difference between the selected voltage magnitude and the actual voltage magnitude of the short high voltage pulse, and the data processor supplying a corrective signal to the controllable gas pressure regulator to change the gas pressure in the spark gap to decrease the voltage magnitude of the short high voltage pulse if the actual voltage magnitude is greater than the selected voltage magnitude or to increase the voltage magnitude of the short high voltage pulse if the actual voltage magnitude is less than the selected voltage magnitude.


A triggered spark gap may also be employed. In this embodiment, the pressure in the spark gap switch is held high enough so that it does not trigger without an external stimulus. An external stimulus is provided when it is desired to turn on the spark gap switch, for example, at a preprogrammed interval and at the desired voltage after the operator presses the switch to impart the treatment.


The means for providing a signal representative of the actual voltage magnitude may be a resistor divider or a pulse transformer. The data processor may be selected from a group consisting of a field programmable gate array, a complex programmable logic device, a microprocessor or a microcontroller. The pulse generator may be a Blumlein pulse generator. The delivery device may have similar characteristics and properties as presented above.


The apparatus and system may further include a vacuum in the delivery device to assist in keeping a bottom face of the delivery device in contact with the human tissue during the treatment. A retractable needle support may protect the pair of needle electrodes from bending during insertion of the pair of needle electrodes into the human tissue. The ends of the pair of needle electrodes may be retracted into the delivery device and the ends of the pair of needle electrodes may be quickly forced into the human tissue upon actuation of the delivery device.


A further embodiment of the subject matter disclosed herein is directed to methods for providing electrical energy to human tissue to treat a tissue condition. The method includes the steps of generating a short high voltage pulse of energy at a pair of output terminals with a high voltage pulse generator, emitting a spark when the voltage across a spark gap associated with the pulse generator exceeds the dielectric strength of pressurized gas in the spark gap, sensing the pressure of the gas in the spark gap, providing a pressure signal related to the sensed pressure, adjusting the pressure in the spark gap to modify the magnitude of the voltage of the short high voltage pulse generated by the pulse generator, receiving the short high voltage pulse of energy from the pulse generator at a delivery device, and applying the short high voltage pulse of energy to the tissue.


The methods may include the further steps of supplying gas pressure to the spark gap from a controllable gas pressure regulator, selecting an initial voltage magnitude for the short high voltage pulse, determining the actual voltage magnitude of the short high voltage pulse, providing a signal representative of the actual voltage magnitude of the short high voltage pulse, receiving the signal representative of the voltage magnitude of the short high voltage pulse at a data processor, determining any difference between the selected voltage magnitude and the actual voltage magnitude of the short high voltage pulse and supplying a corrective signal to the controllable gas pressure regulator to change the gas pressure in the spark gap to decrease the voltage magnitude of the short high voltage pulse if the actual voltage magnitude is greater than the selected voltage magnitude or to increase the voltage magnitude of the short high voltage pulse if the actual voltage magnitude is less than the selected voltage magnitude.


The step of providing a signal representative of the actual voltage magnitude of the short high voltage pulse may be provided by a resistor divider or by a pulse transformer. Still further steps of the methods may include one or more of the steps of selecting the data processor from a group consisting of a field programmable gate array, a complex programmable logic device, a microprocessor or a microcontroller, disposing an impedance between the high voltage pulse generator and the delivery device to limit the current associated with the short high voltage pulse of energy when the tissue has high conductivity condition, providing a pair of needle electrodes in the delivery device for penetrating into the human tissue, delivering the short high voltage pulse of energy to tissue disposed between the needle electrodes, providing the needle electrodes with uncoated ends, and providing an insulative coating about proximal portions of the needle electrodes.


The methods may further include the step of providing a vacuum in the delivery device to assist in keeping a bottom face of the delivery device in contact with the human tissue during the treatment. Still further steps may include disposing a pair of needle electrodes in said delivery device for penetrating into the human tissue and for delivering the short high voltage pulse of energy to tissue disposed between the needle electrodes, retracting the ends of the pair of needle electrodes into the delivery device, and forcing the ends of the pair of needle electrodes into the human tissue upon actuation of the delivery device. Additional steps may include disposing a pair of needle electrodes in the delivery device for penetrating into the human tissue and for delivering the short high voltage pulse of energy to tissue disposed between the needle electrodes, providing a retractable needle support to protect the pair of needle electrodes from bending during insertion of the pair of needle electrodes into the human tissue, extending the retractable needle support about the ends of the pair of needle electrodes, and retracting said retractable needle support into the delivery device as the pair of needle electrodes are inserted into the human tissue.





BRIEF DESCRIPTION OF THE DRAWINGS

The subject matter disclosed herein, together with its objects and the advantages thereof, may best be understood by reference to the following description taken in conjunction with the accompanying drawings, in which like reference numerals identify like elements in the figures, and in which:



FIG. 1 is an elevational view of an energy delivery device in accordance with the subject matter disclosed herein;



FIG. 2A is a partial longitudinal cross-sectional view of the energy delivery device of FIG. 1;



FIG. 2B is a cut-away perspective view of a dual needle adapter in sealed packaging for the energy delivery device of FIG. 1;



FIG. 2C is an enlarged perspective view of one of the needles in the dual needle adapter of FIG. 2B illustrating a coating which is applied to a portion thereof;



FIG. 2D is a plan view of an alternate needle assembly which has more than two needles for the energy delivery device of FIG. 1;



FIG. 3 is a diagram illustrating a Blumlein pulse generator for delivering high voltage pulses to the energy delivery device of FIG. 1;



FIG. 4 is a diagrammatic view of a user interface for controlling the pulse generator shown in FIG. 3 in accordance with a further aspect of the subject matter disclosed herein;



FIG. 5 is a block diagram of electronic circuitry for monitoring and controlling the pulse generator shown in FIG. 3;



FIGS. 6A and 6B are partial perspective views of an energy delivery device which utilize a needle support which may be extended to protect both needles when the delivery device is not in use;



FIG. 6C is an elevational view of a separate needle support, similar to the needle support in FIGS. 6A-6B, but with a retractable separate needle support provided for each needle;



FIG. 7A is an perspective view of another embodiment of the energy delivery device illustrated in FIG. 1;



FIG. 7B is a partial cross-sectional view of the energy delivery device shown in FIG. 7A, which illustrates another embodiment of a disposable needle assembly with the needle assembly providing protection of the dual needles when the energy delivery device is not in use;



FIGS. 8A and 8B are partial perspective views of an energy delivery device which are similar to FIGS. 6A-6B, but which provide a retractable cylindrical sleeve for protection of the needles when the delivery device is not in use; and



FIG. 9 is a flowchart illustrating typical steps which may be employed to cool the top surface of the skin, prior to, during, and/or after a treatment.





DESCRIPTION OF THE PREFERRED EMBODIMENTS

It will be understood that the subject matter disclosed herein may be embodied in other specific forms without departing from the spirit thereof. The present examples and embodiments, therefore, are to be considered in all respects as illustrative and not restrictive, and the subject matter disclosed is not to be limited to the details presented herein.


The apparatus, systems and methods of the subject matter disclosed herein deliver pulsed electrical fields to sub dermal tissue of a human being. One such use is for the treatment of cellulite, by targeting fat cells and connective tissue. Other uses may include potential treatment of cancer, such as leukemia, may also be of interest.


One embodiment of an electrical pulse delivery device, generally designated 100, is shown in FIG. 1. Delivery device 100 provides ultra-short pulses of energy for an intracellular electro-manipulation or other treatment in accordance with the subject matter disclosed herein. A button 102 is disposed on the delivery device, such as near the top of delivery device 100. Button 102 operates as an electrical switch to provide electrical energy from a pulse generator 300 in FIG. 3 via a pair of input terminals 110-111 to a pair of needles 104 and 105 disposed on delivery device 100. For example, when button 102 is depressed, delivery device 100 provides pulses of energy from the pulse generator 300 to the pair of needles 104 and 105 for the intracellular electro-manipulation treatment. Upon release of button 102, the electrical path between the pulse generator 300 and the needles 104 and 105 is interrupted, and further treatment is automatically terminated.


A portion of delivery device 100 includes a generally cylindrical housing 106. As seen in FIG. 2A, a lower end 107 of the housing 106 is suitable for receiving an adapter 108. Adapter 108 has a radially extending flange 109 of larger diameter than housing 106, which may assist a user in holding delivery device 100 during a treatment procedure. A dual needle assembly 114 (FIG. 2A) fits onto the bottom end of adapter 108. Dual needle assembly 114 may have an exterior domed surface 112 through which the pair of needles 104 and 105 extends downwardly.


Preferably, the dual needle assembly 114 is disposable and is sealed for hygienic reasons. As shown in FIG. 2B, dual needle assembly 114 may come prepackaged. A lower package portion 210 provides a chamber 211 for protecting needles 104-105 prior to use, and an upper package portion 212 seals to lower package portion 210. Since needles 104 and 105 are intended to be electrically conductive to supply electrical energy to tissue to be treated, most of the remainder of assembly 114 is preferably constructed of an insulative material, such as an ABS (acrylonitrile butatiene styrene) plastic. Side portions of assembly 114 may provide a frictional fit to retain the assembly 114 onto the lower end of the adapter 108. Alternatively, assembly 114 may be threaded to secure assembly 114 to adapter 108.


Needles 104 and 105 are preferably micro-needles, which may be made, for example, from solid 30 gauge stainless steel (316) stock. The tips of needles 104 and 105 may be hypodermic-style. That is, the tips may be formed with cutting edges to facilitate relatively painless and easy penetration of the skin. FIG. 2C illustrates one of the needles 104. As illustrated in FIG. 2C, a coating 228 is preferably applied to a proximal end 220 of needle 104, with the distal end 222 uncoated. An underside 226 of the head 224 of needle 104 may also have the coating 228 applied thereto.


The purpose of coating 228 at the upper end 220 of needle 104 is to avoid application of stronger electrical fields by delivery device 100 to dermal tissues while the lower uncoated end 222 is applying electrical fields to sub dermal tissue, such as fat cells and connective tissue called septae. Coating 228 is preferably relatively uniform in thickness and without any voids, such as pinholes. For example, coating 228 may be a parylene coating, which is deposited by a vapor-phase deposition polymerization process. Parylene has a low coefficient of friction, very low permeability to moisture and a high dielectric strength. Other examples for the coating 228 include polyimide, polyester, diamond, Teflon and siloxane. While needle 104 is shown in FIG. 2C and described above, it will be appreciated that needle 105 is similar to needle 104, including the coating 228. For hygienic reasons, the entire micro needle assembly 114, including needles 104 and 105, may be disposable.


For example, the needles 104 and 105 may extend about 5 mm to 15 mm, and, typically about 8 mm, from the bottom surface 112 of delivery device 100, with the proximal 3 mm to 5 mm of needles 104 and 105 having the insulating parylene coating 228. The parylene coating 228 is intended to extend through the dermis during a treatment procedure, thus protecting the dermis by substantially reducing the electrical field between needles 104 and 105 in the vicinity of the dermis. By way of example, the dual-needle delivery device 100 discussed herein may subject the target cells to a pulse in the range of 10 nanoseconds to 500 nanoseconds (10×10−9 seconds to 500×10−9 seconds) having an average electric field strength (“E”) of about 10 kV/cm to 50 kV/cm, and, typically of about 30 kV/cm, at a pulse rate of about 1 to 10 pulses per second.


With reference to FIG. 2A, the apparatus and system may also include one or more contact switches 116-118 at the distal face 114 of the delivery device 100 in contact with skin. A necessary condition for delivery of the electrical pulse can be activation of the contact switches when skin is pressed against the distal face 114, including one or any combination of the contact switches 116-118. This ensures that there is no significant air gap between the face 114 of the delivery device 100 and the skin, and consequently, the likelihood of energy delivery occurring on top of the skin surface is reduced or eliminated.


An alternate multiple needle array 115, which provides more than two needles 104-105 in the dual needle assembly 114, is shown in FIG. 2D. In the example of FIG. 2D, the multiple needle array 115 provides six needles N1 through N6. These needles may be partially insulated, as with needles 104-105. By way of example, voltage can be first applied between needles N1 and N2, then between needles N1 and N3, and so on. For N needles, the distinct number of pairs is (N*N−(N(N(N+1)/2))=36−21=15. These 15 pairs are N1-N2, N1-N3, N1-N4, N1-N5, N1-N6, N2-N3, N2-N4, N2-N5, N2-N6, N3-N4, N3-N5, N3-N6, N4-N5, N4-N6 and N5-N6. Voltage can be applied to all of these distinct pairs, or to some of these distinct pairs. Other configurations and choices of pairs are also contemplated.


As described above, the system delivers very short pulses of low energy to the tissue being treated. The schematic diagram in FIG. 3 illustrates a pulse generator, generally designated 300, of the Blumlein transmission line type, for generating low energy/high voltage pulses of short duration. In this embodiment, the ultra-short pulses are generated by pulse generator 300, but such pulses could also be generated using a pulse-forming network or by any other suitable methods. Pulse generator 300 generally consists of a high voltage power supply 302, four sections of coaxial cable 306-309 and a spark gap 318. A resistor 304 may be disposed between the high voltage power supply and the first coaxial section 306.


Inner conductors 310 and 312 of coaxial sections 306 and 307 connect to one of the leads of the spark gap 318. The other lead of spark gap 318 connects to the outer sheath 313 of coaxial section 307. Near coaxial sections 308 and 309, the outer sheaths 311 and 313 of coaxial sections 306 and 307 are grounded, as well as the inner conductors 314 and 316 of coaxial sections 308 and 309. At the opposite ends of coaxial sections 308 and 309, the outer sheaths 315 and 317 are connected together at a node 325. Inner conductor 314 of coaxial section 308 is connected to a pair of resistors 320 and 321, and inner conductor 316 of coaxial section 309 is similarly connected to another pair of resistors 322 and 323. Opposite ends of resistors 320 and 322 are connected to node 325. Opposite ends of resistors 321 and 323 are connected to needles 104 and 105, respectively. Collectively, resistors 320-323 form a balanced resistor network at the output of pulse generator 300.


The spark gap 318 may be filled with nitrogen or any other suitable gas. The internal pressure of the nitrogen in the spark gap may be regulated to control the voltage at which the spark gap breaks down, thereby also controlling the amount of energy delivered to the needles 104 and 105 by the pulse generator 300. When the spark gap breaks down, a high voltage, short duration pulse will be delivered to the needles through the balanced resistor network consisting of resistors 320-323. In an embodiment, all of resistors 320-323 may be about 50 ohms. The magnitude of the voltage delivered to the patient is determined by the spark gap 318. The spark gap will breakdown when the voltage across its electrodes exceeds the dielectric strength of the gas in the spark gap. The dielectric strength of the gas is controlled by the gaseous pressure within the spark gap. Thus, controlling the gaseous pressure also controls the magnitude of the voltage delivered.


In order to safely and reliably deliver short high-voltage pulses to a patient during a treatment procedure, adequate controls and monitors are required. The subject matter disclosed herein is also concerned with such controls and monitors. The first set of controls relate to ensuring that the voltage delivered to the patient is correct and accurate. The voltage delivered to the patient is selected by the operator through a user interface module, generally designated 400 in FIG. 4. Module 400 may include a power entry module with a power switch 402, indicators 404 for power on and alerts, such as light emitting diodes (LEDs), an emergency stop switch 406 and a touch sensitive screen 408 for displaying and selecting operating modes, menus of available options, and the like.


Associated with user interface module 400 is a high voltage control module 420. Module 420 may include a high voltage enable switch 422, a probe (also referred to herein as delivery device 100) calibration connection 424, a high voltage output 426 for supplying the high voltage pulses to delivery device 100, and a low voltage connection 428 for the delivery device 100. A regulator 432 monitors and supplies nitrogen gas to spark gap 318 from a source of compressed nitrogen 430.



FIG. 5 illustrates, in block diagram format, the electronic circuitry, generally designated 500, which may be contained within the high voltage control module 420 shown in FIG. 4. Much of circuitry 500 may be on a interface circuit board 502. Circuitry 500 is monitored and controlled by a complex programmable logic device (CPLD) 504. Alternatively, CPLD 500 may be a field-programmable gate array (FPGA) or any suitable microprocessor or microcontroller. The high voltage (HV) pulses generated by pulse generator 300 and supplied to delivery device 100 may be monitored in any of a variety of ways. For example, the HV pulses may be monitored by sensing the voltage across one of the resistors 321 or 323 in FIG. 3. A resistor divider (not shown) may be connected across resistor 321 to reduce the high voltage pulse to a lower level more suitable for the electronic circuitry 500. A pulse transformer 506 may be used to supply the pulse to circuitry 500, while also providing DC isolation between the circuitry and the pulse generator. A threshold detector 508 receives pulse signals from transformer 506 and provides pulse detection information to CPLD 504 via line 509 if any pulse exceeds a predetermined threshold.


CPLD 504 enables the HV power supply 302 via line 510. Signal conditioning circuitry 512 monitors the output voltage of the HV power supply on line 513. In this respect, signal conditioning circuitry 512 may have a voltage reference for comparison purposes. An analog to digital converter (ADC) 514 supplies the monitored information to CPLD 504 via a serial peripheral interface (SPI) bus. The SPI bus is also routed to other portions of the circuitry 500, such as to an isolated SPI interface 516 which may supply information to external sources, such as a master data controller 518.


Digital information concerning falling edge threshold and rising edge threshold is provided from peak detector 526, via lines 528 and 529, to a digital to analog converter (DAC) 524. DAC 524 then provides a pressure set signal on line 530 to pressure control 432 to regulate the pressure of nitrogen in the spark gap 318. As previously explained, control of the pressure in spark gap 318 controls the magnitude of the high voltage pulses generated by pulse generator 300. Pressure feedback information is provided from pressure control 432 on line 531 to the signal conditioning and thence to ADC where it is sent via the SPI bus to CPLD 504.


The CPLD or microprocessor 504 controls the gas pressure regulator 432 in setting and monitoring the gaseous pressure within the spark gap 318. The microprocessor also monitors the voltages going to the Blumlein pulse generator 300 and the voltage across the load resistors 320-323 on the output of the pulse generator using resistor dividers, pulse transformer 506 and analog to digital converter 514. Prior to use on the patient, the delivered voltage at the needles 104-105 is adjusted to ensure a proper value. This process starts by setting the spark gap pressure to an empirically generated first guess estimated to give the proper voltage. The Blumlein pulse generator 300 is fired and the pulse generator voltages are monitored. The pressure is then adjusted based on the difference between the measured output voltage and the desired output voltage. The adjustment process continues until the difference between the measured and desired is within an acceptable level.


The adjustment is preferably proportional control. However, the adjustment could also include differential and integral control. The control can be based on either the monitored pulse generator input or output signal. Using the pulse generator input signal requires monitoring the input voltage and holding the peak value from the time that the high voltage power supply (HVPS) 302 is activated until the pulse is delivered at the needles 104-105. Delivery of the pulse can be detected by either sensing a rapid decrease in the pulse generator input, a pulse on the pulse generator output or an optical signal from the spark gap. Using the pulse generator output signal may require detecting the rising and falling edges of the pulse and averaging the values between these two edges.


An alternate method for monitoring the voltage is to implement a calibration port 424 on the system. This calibration port 424 allows the distal end of the delivery device 100 to be connected to the console 420. The distal electrode voltage is then monitored and the spark gap pressure is controlled to ensure that the distal electrode voltage matches the desired output voltage within appropriate limits. This method will compensate for any losses or changes to the voltage induced by the patient cable and/or the delivery device.


A second set of controls is related to controlling the pulse delivery rate. The control of the pulse delivery rate is selected by the operator through the user interface 400. The microprocessor 504 controls the delivery of each pulse by commanding the HVPS 302 to go to a predetermined high voltage level that is selected to be higher than the desired voltage delivered to the patient. In this embodiment, the microprocessor controls the HVPS command through a field programmable gate array (FPGA) 504. This FPGA buffers the command to the HVPS 302 and controls the slope of the command to mitigate against excessive overshoot of the HVPS output. The output of the HVPS is feed into the pulse generator 300 through a series resistor and appropriate protection diodes. The microprocessor 504 will initiate these pulses at the rate determined by the user interface 400, such as by selection on screen 408. Several monitors ensure that the pulses delivered are within predetermined parameters. If any of these monitors indicate that the pulse has not been delivered, microprocessor 504 will inhibit any new pulses from being initiated and will alert the operator to the problem.


One risk for any high voltage delivery system is that some other component in the system breaks down at a lower voltage than the spark gap 318. If this occurs, no pulse, an improperly shaped pulse or a lower voltage pulse could be delivered to the patient. If any failures within the system are detected or if delivered pulses are not within established parameters, subsequent delivery of pulses will be terminated and the operator will be alerted.


In accordance with another aspect, the subject matter disclosed herein may be used by a physician to treat cellulite by inducing selective adipocyte death in the subcutaneous fat layer (SFL), or cutting of collageneous septae, or both, such as by plasma spark discharge. Adipocyte death may be caused by apoptosis or necrosis, both considered cell lysis. The dead adipocytes will be naturally reabsorbed by the body. Fewer adipocytes in the SFL will reduce the pressure on the dermis, blood vessels and lymphatic system in the affected area, which will typically lead to an improved cosmetic experience. The subject matter disclosed herein may also have an effect of cutting or ablating or denaturing septae that tether the dermis to the underlying fascia. These effects on the septae will lead to improvement in the appearance of cellulite dimples, for example, by releasing the tension on the dermis.


In accordance with a further aspect of the subject matter disclosed herein, needles 104-105 may be force assisted for insertion into the skin. One of the problems associated with small gauge needles, such as about 30 gauge needles, is that they tend to bend while insertion into the skin if the needles are not substantially perpendicular to the skin during insertion. Thus, care must be taken while inserting the needles into the skin to apply forces perpendicular to the skin surface, and in the direction of the needles, to avoid bending the needles. Thus, in accordance with another aspect of the subject matter disclosed herein, the needles 104-105 may be retractable into the delivery device 100. Upon actuation, the needles 104-105 are quickly forced or shot out to their full distal position, as illustrated in FIG. 1. The needles 104-105 are then held in this distal position by mechanical means or by application of force from the power source while therapeutic electrical pulses are delivered through the needles to the patient. Following the electrical pulse treatment, the needles may again be retracted into the delivery device 100.


A flowchart 900 in FIG. 9 illustrates methods of cooling the top layer of the skin may be cooled prior to treatment, during treatment, after treatment, or any combination thereof. At step 901, the top surface of the skin is cooled prior to performing the treatment. At step 902, the needles 104-105 of the delivery device 100 are inserted into the skin, and the cooling of the surface of the skin continues. At step 903, the treatment is performed, and at step 904, the cooling of the top surface of the skin continues. At step 905, the needles are withdrawn from the skin and at step 906, the cooling of the top surface of the skin continues. While this example contemplates cooling of the top surface of the skin prior to, during and after treatment, it will be appreciated that cooling may be separately employed in any of the above steps, or in any combination of the above steps. Examples of methods of cooling the top layer of the skin are contact with ice, contact with a cold plate, and/or spraying with a cold fluid or cryogen. Similarly, if desired, the needles may also be cooled. This will assist in preventing any undesirable heating of the top layer of the skin and any resulting untoward effects. This may also reduce any discomfort during treatment.


In accordance with yet another aspect of the subject matter disclosed herein, an energy delivery device 600 may be provided with a retractable needle support 610 or 620, as illustrated by the embodiments shown in FIGS. 6A, 6B and 6C. In accordance with this aspect of the subject matter disclosed herein, delivery device 600 and needles 104-105 are provided with a retractable needle support 610 which surrounds the needles 104-105 and which extends out of the bottom surface 612 of the delivery device 600 as shown in FIG. 6B. Upon insertion of the needles 104-105 into the skin of a patient, the retractable support 610 comes into contact with the skin of the patient and the retractable support 610 is pushed back into the interior of the delivery device 600 as shown in FIG. 6A, thereby permitting the ends of the needles to penetrate the skin for the electric pulse treatment of the tissue. The retractable support 610 thus holds the needles 104-105 in position during insertion and assists in preventing bending of the needles during insertion.


A desirable characteristic of the retractable support 610 is to house the needles 104-105 in a manner which protects the needles from bending or from encountering other damage when not in use. For example, the retractable support 610 may be a tube-like structure of a length sufficient to cover the ends of the needles 104-105, with internal diameters sufficiently large to accommodate the smaller diameter needles, but also of sufficiently small diameter to prevent any significant bending of the needles 104-105 during insertion. Retractable support 610 may be of any suitable shape, such as of a modified oval cross-sectional shape shown in FIGS. 6A and 6B, cylindrical cross-sectional shape, square, rectangular, or other cross-sectional shapes.


Alternatively, a separate retractable support 620 in FIG. 6C may be used about each needle 104 or 105. Retractable support 602 may be of any suitable shape, such as the cylindrical cross-sectional shape illustrated in FIG. 6C. In a manner similar to retractable support 610, each of retractable supports 620 may be pushed back into the interior of the delivery device 600 as the retractable supports come into contact with the skin, thereby permitting the ends of the needles to penetrate the skin for the electric pulse treatment of the tissue.


Either of the retractable supports 610 or 620 may be biased by light pressure supplied, such as by a spring 622 shown in FIG. 6C to extend the supports about the ends of the needles 104-105 when not in use, to retract into the delivery device 600 when in use, and to again extend about the ends of the needles when the treatment is completed. Such a retractable support will also protect the needles from bending or other damage when not in use and may also protect the physician or staff from injury when not in use.


In accordance with another aspect of the subject matter disclosed herein, the delivery device 100 may utilize vacuum-assisted skin engagement. Current and prior art procedures require the physician to hold a delivery device perpendicular to the skin with moderate pressure. If the orientation of the delivery device changes, or if the pressure of the delivery device 100 against the surface of the skin changes, the electrical conditions between the adipose tissue, the pulse generator 300 and the two needles 104-105 may change, resulting in a higher than desired current level. Additionally, air may become entrapped between the needles which may provide a leakage current path.


Illustrated in FIGS. 7A and 7B is a delivery device 700, which may use a light vacuum to assist in pulling the surface of the skin into contact with the bottom surface 704 of the delivery device. Further, once the bottom surface 704 of the delivery device 700 is in engagement with the skin of the patient, the light vacuum assists in retaining the bottom surface of the delivery device in contact with the skin. Thus, any effects due to movement of the patient or the physician are minimized as the patient's skin tends to move with any corresponding movement of the delivery device. For example, the vacuum may be supplied via an orifice 702 in the distal or bottom face 704, such as between needles 104 and 105. Orifice 702 is in the reusable module portion 712 of device 700 which is also in vacuum communication with an internal vacuum passageway 708 in the disposable module portion 710 of device 700. As shown in FIG. 7B, the portion of orifice 702 which meets the bottom surface 704 of the disposable module 710 may be enlarged for application of the vacuum thereat to a correspondingly larger area of the skin. A goal of using a vacuum is to ensure good contact of the delivery device 100 with the skin.


Another embodiment of a disposable needle assembly 720 is shown in FIG. 7B for use with energy delivery device 700. Needles 104-105 electrically connect to delivery device 700, such as by a mini banana plug interface 722, to receive high voltage pulses which are provided by one of the electrical lines 714 or 716 (FIG. 7A) connected to the back end 715 of device 700. The other line 716 or 714 may be used for control signals. Needle assembly 720 includes an outer sleeve 724. The upper end 725 of outer sleeve 724 fits partially into an annular recess 726 defined in the front end 712 of device 700. A ring 728 and 729 of closed cell foam is internally disposed about each needle 104 and 105, respectively. These foam rings 728-729 tend to bias the outer sleeve 724 to the position shown in FIG. 7B where the needles 104-105 are not exposed, but are substantially within outer sleeve 724.


However, when the bottom face 704 of the outer sleeve 724 is applied against the skin of a patient, the foam rings 728-729 are compressed such that needles 104-105 penetrate the skin. At the same time, the upper end 725 of outer sleeve 724 moves upwardly within the annular recess 726. If desired, the limit of needle penetration in the skin can be provided when the upper end 725 contacts the end of the annular groove 726, or when the foam rings 728-729 are fully compressed. The foam rings may be of a foam material which has memory to return to its uncompressed state when a treatment is completed. For example, foam rings 728-729 may be made of a closed cell foam material.


Another embodiment for protecting for the needles 104-105 is shown in FIGS. 8A and 8B. In this embodiment, a sleeve 810 may be retracted for treatment of a patient and the sleeve 810 may be extended when the delivery device 800 is not in use. For example, sleeve 810 may be biased to the extended position shown in FIG. 5B by a spring or the like, in a similar manner to spring 622 in FIG. 6C. Sleeve 810 may be cylindrical in cross-section shape, or oval or other shapes. When sleeve 810 is fully extended, as shown in FIG. 8B, a front edge 814 of sleeve 810 extends forwardly of the tips of needles 104-105. The embodiment shown in FIGS. 8A-8B has some advantages when delivery device uses vacuum assisted treatment. For example, when delivery device 800 is provided with a vacuum orifice, such as orifice 702 shown in FIG. 7B, the entire area within sleeve 810 will be under vacuum as soon as the front edge 814 of sleeve 810 comes into contact with the skin. This will assist in pulling the skin into contact with the needles 104-105 and will also help prevent lateral movement of the delivery device 800 thereby preventing bending of needles 104-105 during insertion.


While particular embodiments of the subject matter disclosed herein have been shown and described, it will be obvious to those skilled in the art that changes and modifications may be made therein without departing from the invention in its broader aspects.

Claims
  • 1. A system for providing electrical energy to human tissue to treat a tissue condition, said system comprising: a high voltage pulse generator for generating a short high voltage pulse of energy at a pair of output terminals;said pulse generator including a spark gap which contains a pressurized gas and which emits a spark when the voltage across the spark gap exceeds the dielectric strength of the gas in the spark gap;a sensor for sensing the pressure of the gas in the spark gap and for providing a pressure signal related to the sensed pressure;means responsive to the pressure signal for adjusting the pressure in the spark gap to modify the magnitude of the voltage of the short high voltage pulse generated by the pulse generator;a delivery device for receiving the short high voltage pulse of energy from the pulse generator and for applying the short high voltage pulse of energy to said tissue; andat least a pair of needle electrodes disposed in said delivery device for penetrating into the human tissue and for delivering the short high voltage pulse of energy to tissue disposed between the needle electrodes;said spark gap, said sensor and said means for adjusting the pressure in the spark gap all being disposed exterior to said pair of needle electrodes.
  • 2. The system in accordance with claim 1, wherein said needle electrodes of the delivery device have uncoated ends and have an insulative coating applied about proximal portions of the needle electrodes.
  • 3. The system in accordance with claim 1, wherein the delivery device includes more than two needle electrodes such that different pairs of needle electrodes may be selected for delivery of the short high voltage pulse of energy to tissue between the selected pair of needle electrodes.
  • 4. The system in accordance with claim 1, wherein said short high voltage pulse is about 10 nanoseconds to 500 nanoseconds in duration.
  • 5. The system in accordance with claim 1, wherein said short high voltage pulse provides an electric field strength of about 10 kilovolts/centimeter to 50 kilovolts/centimeter in the tissue.
  • 6. The system in accordance with claim 1, wherein a vacuum in the delivery device assists in keeping a bottom face of the delivery device in contact with the human tissue during the treatment.
  • 7. The system in accordance with claim 1, wherein the ends of the needle electrodes are retracted into the delivery device and the ends of the needle electrodes are quickly forced into the human tissue upon actuation of the delivery device.
  • 8. The system in accordance with claim 1, further comprising: a retractable needle support to protect the needle electrodes from bending during insertion of the needle electrodes into the human tissue.
  • 9. The system in accordance with claim 8, said retractable needle support extending about the ends of the needle electrodes, and said retractable needle support retracting into the delivery device as the needle electrodes are inserted into the human tissue.
  • 10. A system for providing electrical energy to human tissue to treat a tissue condition, said system comprising: a high voltage pulse generator for generating a short high voltage pulse of energy at a pair of output terminals;said pulse generator including a spark gap which contains a pressurized gas and which emits a spark when the voltage across the spark gap exceeds the dielectric strength of the gas in the spark gap;a sensor for sensing the pressure of the gas in the spark gap and for providing a pressure signal related to the sensed pressure;means responsive to the pressure signal for adjusting the pressure in the spark gap to modify the magnitude of the voltage of the short high voltage pulse generated by the pulse generator;a delivery device for receiving the short high voltage pulse of energy from the pulse generator and for applying the short high voltage pulse of energy to said tissue;a controllable gas pressure regulator to supply gas pressure to the spark gap;means for selecting an initial voltage magnitude for the short high voltage pulse;means for determining the actual voltage magnitude of the short high voltage pulse and for providing a signal representative of the actual voltage magnitude of the short high voltage pulse; anda data processor for receiving the signal representative of the voltage magnitude of the short high voltage pulse, said data processor determining any difference between the selected voltage magnitude and the actual voltage magnitude of the short high voltage pulse; and said data processor supplying a corrective signal to the controllable gas pressure regulator to change the gas pressure in the spark gap to decrease the voltage magnitude of the short high voltage pulse if the actual voltage magnitude is greater than the selected voltage magnitude or to increase the voltage magnitude of the short high voltage pulse if the actual voltage magnitude is less than the selected voltage magnitude.
CROSS-REFERENCE TO RELATED APPLICATIONS

This patent application claims the benefit of, and the right of priority to, U.S. provisional patent application Ser. No. 61/050,814, filed on May 6, 2008.

US Referenced Citations (244)
Number Name Date Kind
1645215 Bauer Oct 1927 A
1814791 Ende Jul 1931 A
1916722 Ende Jul 1933 A
2185367 Blumlein Jan 1940 A
3551677 Brewster Dec 1970 A
3571746 DeTemple et al. Mar 1971 A
4016886 Doss et al. Apr 1977 A
4667161 Wilcox May 1987 A
4878793 Hewison Nov 1989 A
4917093 Dufresne et al. Apr 1990 A
4955378 Grasso Sep 1990 A
4969468 Byers et al. Nov 1990 A
5019034 Weaver et al. May 1991 A
5085639 Ryan Feb 1992 A
5088982 Ryan Feb 1992 A
5118969 Ikezi et al. Jun 1992 A
5137817 Busta et al. Aug 1992 A
5138270 Nakata et al. Aug 1992 A
5211660 Grasso May 1993 A
5382240 Lam Jan 1995 A
5389069 Weaver Feb 1995 A
5458597 Edwards et al. Oct 1995 A
5464386 Hofmann Nov 1995 A
5527352 Vona Jun 1996 A
5536267 Edwards et al. Jul 1996 A
5593429 Ruff Jan 1997 A
5630426 Eggers et al. May 1997 A
5660836 Knowlton Aug 1997 A
5674267 Mir et al. Oct 1997 A
5688233 Hofmann et al. Nov 1997 A
5697882 Eggers Dec 1997 A
5702359 Hofmann et al. Dec 1997 A
5775753 Tetelboim Jul 1998 A
5778894 Dorogi et al. Jul 1998 A
5810762 Hofmann Sep 1998 A
5868744 Willmen Feb 1999 A
5871469 Eggers Feb 1999 A
5871524 Knowlton Feb 1999 A
5885211 Eppstein et al. Mar 1999 A
5911223 Weaver et al. Jun 1999 A
5928159 Eggers et al. Jul 1999 A
5947964 Eggers et al. Sep 1999 A
5954717 Behl et al. Sep 1999 A
5968006 Hofmann Oct 1999 A
5968041 Edwards Oct 1999 A
5993434 Dev et al. Nov 1999 A
6010613 Walters et al. Jan 2000 A
6014584 Hofmann et al. Jan 2000 A
6027501 Goble et al. Feb 2000 A
6043066 Mangano et al. Mar 2000 A
6050992 Nichols Apr 2000 A
6055453 Hofmann et al. Apr 2000 A
6068650 Hofmann et al. May 2000 A
6086585 Hovda et al. Jul 2000 A
6106524 Eggers et al. Aug 2000 A
6107699 Swanson Aug 2000 A
6117660 Walters et al. Sep 2000 A
6120493 Hofmann Sep 2000 A
6135990 Heller et al. Oct 2000 A
6135998 Palanker Oct 2000 A
6149620 Baker Nov 2000 A
6174308 Goble et al. Jan 2001 B1
6176857 Ashley Jan 2001 B1
6181964 Hofmann et al. Jan 2001 B1
6190381 Olsen Feb 2001 B1
6208893 Hofmann Mar 2001 B1
6210402 Olsen et al. Apr 2001 B1
6212433 Behl Apr 2001 B1
6216034 Hofmann et al. Apr 2001 B1
6224592 Eggers et al. May 2001 B1
6228078 Eggers et al. May 2001 B1
6264652 Eggers et al. Jul 2001 B1
6296638 Davison et al. Oct 2001 B1
6309387 Eggers et al. Oct 2001 B1
6312428 Eggers et al. Nov 2001 B1
6326177 Schoenbach et al. Dec 2001 B1
6334856 Allen et al. Jan 2002 B1
6346103 Korsec et al. Feb 2002 B1
6350262 Ashley Feb 2002 B1
6377854 Knowlton Apr 2002 B1
6377855 Knowlton Apr 2002 B1
6379353 Nichols Apr 2002 B1
6381497 Knowlton Apr 2002 B1
6381498 Knowlton Apr 2002 B1
6387380 Knowlton May 2002 B1
6402742 Blewett et al. Jun 2002 B1
6405090 Knowlton Jun 2002 B1
6413255 Stern Jul 2002 B1
6413256 Truckai et al. Jul 2002 B1
6416507 Eggers et al. Jul 2002 B1
6416508 Eggers et al. Jul 2002 B1
6425873 Marchitto et al. Jul 2002 B1
6425912 Knowlton Jul 2002 B1
6430446 Knowlton Aug 2002 B1
6443914 Costantino Sep 2002 B1
6453202 Knowlton Sep 2002 B1
6453203 Yamazaki Sep 2002 B1
6461350 Underwood et al. Oct 2002 B1
6461354 Olsen et al. Oct 2002 B1
6461378 Knowlton Oct 2002 B1
6470216 Knowlton Oct 2002 B1
6475191 Tamura et al. Nov 2002 B2
6482201 Olsen et al. Nov 2002 B1
6491669 Ebara Dec 2002 B2
D469179 Nakagami Jan 2003 S
6503231 Prausnitz et al. Jan 2003 B1
6514248 Eggers et al. Feb 2003 B1
6516223 Hofmann Feb 2003 B2
6520950 Hofmann et al. Feb 2003 B1
6567694 Hayakawa May 2003 B2
6569149 Dev et al. May 2003 B2
6569159 Edwards et al. May 2003 B1
6572613 Ellman et al. Jun 2003 B1
6582237 Jacobson Jun 2003 B2
6589786 Mangano et al. Jul 2003 B1
6603998 King et al. Aug 2003 B1
6616631 Takagi Sep 2003 B2
6632193 Davison et al. Oct 2003 B1
6632220 Eggers et al. Oct 2003 B1
6632221 Edwards et al. Oct 2003 B1
6637998 Langan et al. Oct 2003 B2
6638254 Nakagami Oct 2003 B2
6641580 Edwards et al. Nov 2003 B1
6656167 Numao Dec 2003 B2
6673072 Garito et al. Jan 2004 B1
6676638 Takagi Jan 2004 B2
6697670 Chomenky et al. Feb 2004 B2
6730075 Palanker May 2004 B2
6733485 Whitehurst et al. May 2004 B1
6743211 Prausnitz et al. Jun 2004 B1
6760627 Carter et al. Jul 2004 B2
6766202 Underwood et al. Jul 2004 B2
6773431 Eggers et al. Aug 2004 B2
6780178 Palanker Aug 2004 B2
6782283 Schmidt et al. Aug 2004 B2
6785569 Schmidt et al. Aug 2004 B2
6786891 Hiejima Sep 2004 B2
6795728 Chornenky et al. Sep 2004 B2
6821274 McHale et al. Nov 2004 B2
6831377 Yampolsky et al. Dec 2004 B2
6855127 Nakagami Feb 2005 B2
6881213 Ryan et al. Apr 2005 B2
6889089 Behl et al. May 2005 B2
6892099 Jaafar et al. May 2005 B2
6896672 Eggers et al. May 2005 B1
6913605 Fletcher Jul 2005 B2
6918907 Kelly et al. Jul 2005 B2
6920883 Bessette et al. Jul 2005 B2
6921399 Carmel et al. Jul 2005 B2
6923793 Ishida Aug 2005 B2
6949096 Davison Sep 2005 B2
6961603 Merilainen Nov 2005 B2
6974453 Woloszko et al. Dec 2005 B2
6994706 Chornenky et al. Feb 2006 B2
7004942 Laird et al. Feb 2006 B2
7006874 Knowlton et al. Feb 2006 B2
7010356 Jog et al. Mar 2006 B2
7022121 Stern Apr 2006 B2
7048718 Mithiue May 2006 B1
7115123 Knowlton Oct 2006 B2
7150746 DeCesare Dec 2006 B2
7179255 Lettice et al. Feb 2007 B2
7189230 Knowlton Mar 2007 B2
7217265 Hennings et al. May 2007 B2
7229436 Stern Jun 2007 B2
7238185 Palanker Jul 2007 B2
7270658 Woloszko et al. Sep 2007 B2
7278993 Kelly Oct 2007 B2
7357802 Palanker Apr 2008 B2
20010025176 Ellsberry et al. Sep 2001 A1
20010049522 Eggers et al. Dec 2001 A1
20020010491 Schoenbach et al. Jan 2002 A1
20020034796 Shastri et al. Mar 2002 A1
20020077627 Johnson et al. Jun 2002 A1
20020087155 Underwood et al. Jul 2002 A1
20020120260 Morris et al. Aug 2002 A1
20020120261 Morris et al. Aug 2002 A1
20020128641 Underwood et al. Sep 2002 A1
20020133137 Hofmann Sep 2002 A1
20020133149 Bessette Sep 2002 A1
20020146831 Nolan et al. Oct 2002 A1
20020156471 Stern et al. Oct 2002 A1
20020161418 Wilkens et al. Oct 2002 A1
20020193784 McHale et al. Dec 2002 A1
20020193831 Smith, III Dec 2002 A1
20020198485 Dev et al. Dec 2002 A1
20030009148 Hayakawa Jan 2003 A1
20030009164 Woloszko et al. Jan 2003 A1
20030045867 Marchitto et al. Mar 2003 A1
20030069618 Smith, III et al. Apr 2003 A1
20030083724 Jog et al. May 2003 A1
20030088243 Carmel et al. May 2003 A1
20030097129 Davison et al. May 2003 A1
20030120269 Bessette et al. Jun 2003 A1
20030149451 Chomenky et al. Aug 2003 A1
20030153960 Chornenky et al. Aug 2003 A1
20030170898 Gundersen et al. Sep 2003 A1
20030199866 Stern et al. Oct 2003 A1
20030212396 Eggers et al. Nov 2003 A1
20040000316 Knowlton et al. Jan 2004 A1
20040019371 Jaafar et al. Jan 2004 A1
20040116986 Cantoni et al. Jun 2004 A1
20040153057 Davison Aug 2004 A1
20040158288 Keisari et al. Aug 2004 A1
20040167458 Draghia-Akli et al. Aug 2004 A1
20040181216 Kelly et al. Sep 2004 A1
20040181217 Edwards et al. Sep 2004 A1
20040186466 Chornenky et al. Sep 2004 A1
20040193097 Hofmann et al. Sep 2004 A1
20040204669 Hofmann Oct 2004 A1
20040210214 Knowlton Oct 2004 A1
20040229363 Nolan et al. Nov 2004 A1
20040233944 Dantus et al. Nov 2004 A1
20040249373 Gronemyer et al. Dec 2004 A1
20050080409 Young et al. Apr 2005 A1
20050131402 Ciarrocca et al. Jun 2005 A1
20050171523 Rubinsky et al. Aug 2005 A1
20050182462 Chornenky et al. Aug 2005 A1
20050222565 Manstein Oct 2005 A1
20050228373 Kelly et al. Oct 2005 A1
20050234443 Rioux et al. Oct 2005 A1
20050261672 Deem et al. Nov 2005 A1
20050273092 G. et al. Dec 2005 A1
20050282254 Lulla et al. Dec 2005 A1
20060036210 Zhang et al. Feb 2006 A1
20060036300 Kreindel Feb 2006 A1
20060062074 Gundersen et al. Mar 2006 A1
20060064083 Khalaj et al. Mar 2006 A1
20060074313 Slayton et al. Apr 2006 A1
20060161221 Blackmore et al. Jul 2006 A1
20070010811 Stern et al. Jan 2007 A1
20070060862 Sun et al. Mar 2007 A1
20070060989 Deem et al. Mar 2007 A1
20070088413 Weber Apr 2007 A1
20070129759 Colthurst Jun 2007 A1
20070142881 Hennings Jun 2007 A1
20070239156 Palanker Oct 2007 A1
20070239260 Palanker Oct 2007 A1
20080027428 Palanker Jan 2008 A1
20080039832 Palanker Feb 2008 A1
20080103529 Schoenbach et al. May 2008 A1
20080125774 Palanker May 2008 A1
20080140066 Davison Jun 2008 A1
20080188846 Palanker Aug 2008 A1
Foreign Referenced Citations (4)
Number Date Country
1844750 Oct 2007 EP
455492 Oct 1936 GB
WO 9962593 Dec 1999 WO
WO 03075777 Sep 2003 WO
Related Publications (1)
Number Date Country
20090281540 A1 Nov 2009 US
Provisional Applications (1)
Number Date Country
61050814 May 2008 US